催产素预防产后出血的研究进展

doi:10.12280/gjfckx.20240247

摘要/Abstract

摘要：

产后出血是常见的产科并发症，是导致全球孕产妇死亡的首要原因，子宫收缩乏力是导致产后出血的主要原因。催产素及卡贝催产素等子宫收缩剂是预防和治疗子宫收缩乏力的一线药物，催产素作为预防产后出血的首选药物和世界卫生组织推荐的一线子宫收缩剂，其在不同分娩方式中的用药途径、给药时机、剂量和给药速率等方案尚未达成一致。其中多胎妊娠、肥胖等产后出血高危人群中催产素的使用方案与低危人群不同，现有研究的热点是在产后出血高危人群中，如何以最低剂量达到最佳的预防效果，减少药物的不良反应。综述催产素预防产后出血及其给药方案，总结催产素在不同分娩方式中的应用并对未来的研究方向作出展望。

关键词: 催产素, 产后出血, 自然分娩, 剖宫产, 预防

Abstract:

Postpartum hemorrhage is a common obstetric complication and the leading cause of maternal death worldwide, and weak uterine contraction is the main cause of postpartum hemorrhage. Uterine contractions such as oxytocin and carbe oxytocin are the first-line drugs for the prevention and treatment of weak uterine contraction. Oxytocin, as the first-line uterine contractions recommended by WHO for the prevention of postpartum hemorrhage, has not yet reached a consensus on the medication route, administration time, dosage and rate in different delivery methods. Among them, the use of oxytocin in high-risk groups of postpartum hemorrhage such as multiple pregnancies and obesity is different from that in low-risk groups. Current research focuses on how to achieve the best preventive effect with the lowest dose and reduce the adverse effects of the drugs in high-risk groups of postpartum hemorrhage. This paper reviews the prevention of postpartum hemorrhage with oxytocin and its administration plan. The application of oxytocin in different delivery modes was summarized and the future research direction was prospected.

Key words: Oxytocin, Postpartum hemorrhage, Natural childbirth, Cesarean section, Prevention

杨珂昕, 张龑. 催产素预防产后出血的研究进展[J]. 国际妇产科学杂志, 2024, 51(4): 463-467.

YANG Ke-xin, ZHANG Yan. Research Progress of Oxytocin in Preventing Postpartum Hemorrhage[J]. Journal of International Obstetrics and Gynecology, 2024, 51(4): 463-467.

参考文献 38

[1]	Patek K, Friedman P. Postpartum Hemorrhage-Epidemiology, Risk Factors, and Causes[J]. Clin Obstet Gynecol, 2023, 66(2):344-356. doi: 10.1097/GRF.0000000000000782. pmid: 37130373
[2]	Escobar MF, Nassar AH, Theron G, et al. FIGO Safe Motherhood and Newborn Health Committee. FIGO recommendations on the management of postpartum hemorrhage 2022[J]. Int J Gynaecol Obstet, 2022, 157(Suppl 1):3-50. doi: 10.1002/ijgo.14116.
[3]	WHO recommendation on routes of oxytocin administration for the prevention of postpartum haemorrhage after vaginal birth[M]. Geneva: World Health Organization, 2020.
[4]	Angarita AM, Cochrane E, Bianco A, et al. Prevention of postpartum hemorrhage in vaginal deliveries[J]. Eur J Obstet Gynecol Reprod Biol, 2023, 280:112-119. doi: 10.1016/j.ejogrb.2022.11.021.
[5]	中华医学会妇产科学分会产科学组, 中华医学会围产医学分会. 产后出血预防与处理指南(2023)[J]. 中华妇产科杂志, 2023, 58(6):401-409. doi: 10.3760/cma.j.cn112141-20230223-00084
[6]	Post SE, Rood KM, Kiefer MK. Interventions of Postpartum Hemorrhage[J]. Clin Obstet Gynecol, 2023, 66(2):367-383. doi: 10.1097/GRF.0000000000000785. pmid: 37204172
[7]	Kumaraswami S, Butwick A. Latest advances in postpartum hemorrhage management[J]. Best Pract Res Clin Anaesthesiol, 2022, 36(1):123-134. doi: 10.1016/j.bpa.2022.02.004. pmid: 35659949
[8]	Charles D, Anger H, Dabash R, et al. Intramuscular injection, intravenous infusion, and intravenous bolus of oxytocin in the third stage of labor for prevention of postpartum hemorrhage: a three-arm randomized control trial[J]. BMC Pregnancy Childbirth, 2019, 19(1):38. doi: 10.1186/s12884-019-2181-2.
[9]	Durocher J, Dzuba IG, Carroli G, et al. Does route matter? Impact of route of oxytocin administration on postpartum bleeding: A double-blind, randomized controlled trial[J]. PLoS One, 2019, 14(10):e0222981. doi: 10.1371/journal.pone.0222981.
[10]	Ashwal E, Amikam U, Wertheimer A, et al. Route of postpartum oxytocin administration and maternal hemoglobin decline-A randomized controlled trial[J]. Eur J Obstet Gynecol Reprod Biol, 2022, 272:134-138. doi: 10.1016/j.ejogrb.2022.03.028. pmid: 35305347
[11]	Tita AT, Szychowski JM, Rouse DJ, et al. Higher-dose oxytocin and hemorrhage after vaginal delivery: a randomized controlled trial[J]. Obstet Gynecol, 2012, 119(2 Pt 1):293-300. doi: 10.1097/AOG.0b013e318242da74.
[12]	Son M, Roy A, Grobman WA, et al. Maximum Dose Rate of Intrapartum Oxytocin Infusion and Associated Obstetric and Perinatal Outcomes[J]. Obstet Gynecol, 2023, 141(2):379-386. doi: 10.1097/AOG.0000000000005058. pmid: 36649339
[13]	Soltani H, Hutchon DR, Poulose TA. Timing of prophylactic uterotonics for the third stage of labour after vaginal birth[J]. Cochrane Database Syst Rev, 2010(8):CD006173. doi: 10.1002/14651858.CD006173.pub2.
[14]	Yildirim D, Ozyurek SE. Intramuscular oxytocin administration before vs. after placental delivery for the prevention of postpartum hemorrhage: A randomized controlled prospective trial[J]. Eur J Obstet Gynecol Reprod Biol, 2018, 224:47-51. doi: 10.1016/j.ejogrb.2018.03.012. pmid: 29533864
[15]	Somjit M, Surojananon J, Kongwattanakul K, et al. Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction During Cesarean Delivery: A Randomized, Controlled, Non-Inferiority Trial[J]. Int J Womens Health, 2020, 12:667-673. doi: 10.2147/IJWH.S260073. pmid: 32904472
[16]	Sartain JB, Barry JJ, Howat PW, et al. Intravenous oxytocin bolus of 2 units is superior to 5 units during elective Caesarean section[J]. Br J Anaesth, 2008, 101(6):822-826. doi: 10.1093/bja/aen273. pmid: 18845650
[17]	Beiranvand S, Karimi A, Vahabi S, et al. Comparison of the Mean Minimum Dose of Bolus Oxytocin for Proper Uterine Contraction during Cesarean Section[J]. Curr Clin Pharmacol, 2019, 14(3):208-213. doi: 10.2174/1574884714666190524100214. pmid: 31124424
[18]	Carvalho JC, Balki M, Kingdom J, et al. Oxytocin requirements at elective cesarean delivery: a dose-finding study[J]. Obstet Gynecol, 2004, 104(5 Pt 1):1005-1010. doi: 10.1097/01.AOG.0000142709.04450.bd.
[19]	Jaffer D, Singh PM, Aslam A, et al. Preventing postpartum hemorrhage after cesarean delivery: a network meta-analysis of available pharmacologic agents[J]. Am J Obstet Gynecol, 2022, 226(3):347-365. doi: 10.1016/j.ajog.2021.08.060.
[20]	Sheehan SR, Montgomery AA, Carey M, et al. Oxytocin bolus versus oxytocin bolus and infusion for control of blood loss at elective caesarean section: double blind, placebo controlled, randomised trial[J]. BMJ, 2011,343:d4661. doi: 10.1136/bmj.d4661.
[21]	Lavoie A, McCarthy RJ, Wong CA. The ED90 of prophylactic oxytocin infusion after delivery of the placenta during cesarean delivery in laboring compared with nonlaboring women: an up-down sequential allocation dose-response study[J]. Anesth Analg, 2015, 121(1):159-164. doi: 10.1213/ANE.0000000000000781. pmid: 25902327
[22]	Qian XW, Drzymalski DM, Lv CC, et al. The ED₅₀ and ED₉₅ of oxytocin infusion rate for maintaining uterine tone during elective caesarean delivery: a dose-finding study[J]. BMC Pregnancy Childbirth, 2019, 20(1):6. doi: 10.1186/s12884-019-2692-x.
[23]	Baliuliene V, Vitartaite M, Rimaitis K. Prophylactic Dose of Oxytocin for Uterine Atony during Caesarean Delivery: A Systematic Review[J]. Int J Environ Res Public Health, 2021, 18(9):5029. doi: 10.3390/ijerph18095029.
[24]	Duffield A, McKenzie C, Carvalho B, et al. Effect of a High-Rate Versus a Low-Rate Oxytocin Infusion for Maintaining Uterine Contractility During Elective Cesarean Delivery: A Prospective Randomized Clinical Trial[J]. Anesth Analg, 2017, 124(3):857-862. doi: 10.1213/ANE.0000000000001658. pmid: 28212181
[25]	Tantry TP, Karanth H, Anniyappa S, et al. Intravenous oxytocin regimens in patients undergoing cesarean delivery: a systematic review and network meta-analysis of cluster-based groups[J]. J Anesth, 2023, 37(2):278-293. doi: 10.1007/s00540-022-03132-w.
[26]	Wei CN, Deng JL, Dong JH, et al. The Median Effective Dose of Oxytocin Needed to Prevent Uterine Atony During Cesarean Delivery in Elderly Parturients[J]. Drug Des Devel Ther, 2020, 14:5451-5458. doi: 10.2147/DDDT.S258651.
[27]	Peska E, Balki M, Maxwell C, et al. Oxytocin at elective caesarean delivery: a dose-finding study in women with obesity[J]. Anaesthesia, 2021, 76(7):918-923. doi: 10.1111/anae.15322. pmid: 33227150
[28]	Wei CN, Drzymalski D, Cao YF, et al. The Intraoperative Median Effective Dose of Oxytocin for Preventing Uterine Atony in Parturients with a Prior History of Caesarean Delivery[J]. Clin Drug Investig, 2021, 41(12):1047-1053. doi: 10.1007/s40261-021-01090-x.
[29]	Peska E, Balki M, Pfeifer W, et al. Oxytocin at Elective Cesarean Delivery: A Dose-Finding Study in Pregnant People With Twin Pregnancy[J]. Anesth Analg, 2024, 138(4):814-820. doi: 10.1213/ANE.0000000000006309.
[30]	Gök S, Kaleli MB. Investigation of The Effects of Oxytocin Administration Timing on Postpartum Hemorrhage during Cesarean Section[J]. Medicina(Kaunas), 2023, 59(2):222. doi: 10.3390/medicina59020222.
[31]	Takmaz T, Ozcan P, Sevket O, et al. Less Blood Loss by Earlier Oxytocin Infusion in Cesarean Sections? A Randomized Controlled Trial[J]. Z Geburtshilfe Neonatol, 2020, 224(5):275-280. doi: 10.1055/a-1108-2017.
[32]	Foley A, Gunter A, Nunes KJ, et al. Patients Undergoing Cesarean Delivery After Exposure to Oxytocin During Labor Require Higher Postpartum Oxytocin Doses[J]. Anesth Analg, 2018, 126(3):920-924. doi: 10.1213/ANE.0000000000002401. pmid: 28858899
[33]	Shinohara S, Okuda Y, Hirata S, et al. Association between time from cessation of oxytocin infusion for labor to delivery and intraoperative severe blood loss during cesarean section: a retrospective cohort study[J]. J Matern Fetal Neonatal Med, 2020, 33(9):1532-1537. doi: 10.1080/14767058.2018.1521798. pmid: 30196739
[34]	Jones AJ, Federspiel JJ, Eke AC. Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone[J]. Am J Obstet Gynecol MFM, 2023, 5(2S):100731. doi: 10.1016/j.ajogmf.2022.100731.
[35]	Sun H, Xu L, Li Y, et al. Effectiveness and safety of carboxytocin versus oxytocin in preventing postpartum hemorrhage: A systematic review and meta-analysis[J]. J Obstet Gynaecol Res, 2022, 48(4):889-901. doi: 10.1111/jog.15174.
[36]	McDonagh F, Carvalho J, Abdulla S, et al. Carbetocin vs. oxytocin at elective caesarean delivery: a double-blind, randomised, controlled, non-inferiority trial of low- and high-dose regimens[J]. Anaesthesia, 2022, 77(8):892-900. doi: 10.1111/anae.15714. pmid: 35343585
[37]	Khan M, Balki M, Ahmed I, et al. Carbetocin at elective Cesarean delivery: a sequential allocation trial to determine the minimum effective dose[J]. Can J Anaesth, 2014, 61(3):242-248. doi: 10.1007/s12630-013-0082-9. pmid: 24281981
[38]	Drew T, Balki M, Farine D, et al. Carbetocin at elective caesarean section: a sequential allocation trial to determine the minimum effective dose in obese women[J]. Anaesthesia, 2020, 75(3):331-337. doi: 10.1111/anae.14944. pmid: 31867715